<qa>  What is the rationale of the study?The rationale of the study is the assessment of the clinical activity of Panitumumab in conjunction with standard CisplatinGemcitabine chemotherapy in patients with cholangiocarcinomas and gall bladder carcinomas in 1st-line therapy. 